Admin's Archive
Admin has written 64 article(s) .
Multiple Myeloma Section
Medical Oncology Branch
9000 Rockville Pike
Bldg 10, Room 12N226
Bethesda, MD 20892
National Cancer Institute (NCI)
1-800-4-CANCER (1-800-422-6237)
http://www.cancer.gov/
http://www.cancer.gov/cancertopics/types/myeloma/
National Institutes of Health (NIH)
301-496-4000
Email: NIHinfo@od.nih.gov
http://www.nih.gov/
http://health.nih.gov/topic/MultipleMyeloma/Cancers
Summary
The NIH, a part of the U.S. Department of Health and Human Services, is the primary Federal agency for conducting and supporting medical research. Helping to lead the way toward important medical …
| Brand Name: | |
| Generic Name: | |
| Code Name: | AT9283 |
| Company: | Astex |
| FDA Clinical Phase: | 2 |
Description:
AT9283 is a kinase inhibitor that prevents cell division, thereby stopping the growth of cancer cells. Several Phase 1 clinical trials have shown that AT9283 is safe in patients with blood …
 |
Author: Pat Killingsworth Book Description: Living with Multiple Myeloma is about Pat's struggle to cope with his unexpected illness. But the book is more than an inspirational memoir. Living with Multiple Myeloma provides any myeloma patient or caregiver a clear road map they can use to help navigate safely through today's frustrating health care maze. Purchase Living with Multiple Myeloma |
| Brand Name: | |
| Generic Name: | |
| Code Name: | CEP-18770 |
| Company: | Cephalon |
| FDA Clinical Phase: | 1/2 |
Description:
CEP-18770 is a boronic-acid based proteasome inhibitor that suppresses tumor growth by inhibiting the enzymes that break down important proteins in cancerous cells. Animal studies showed that CEP-18770 demonstrated superior activity to Velcade (bortezomib), and it caused fewer side effects during treatment.
Clinical Trials:
For a list of clinical trials studying CEP-18770 for the treatment of multiple myeloma, see ClinicalTrials.gov.
| Brand Name: | |
| Generic Name: | Marizomib, salinosporamide A |
| Code Name: | NPI-0052 |
| Company: | Triphase Research and Development I Corp |
| FDA Clinical Phase: | 1 |
Description:
Marizomib (NPI-0052, salinosporide A) (news articles) is a novel proteasome inhibitor that suppresses tumor growth by inhibiting the enzymes that break down important proteins in cancerous cells. Marizomib may be used as an alternative treatment to Velcade …
Read the full story »
| Brand Name: | Zolinza |
| Generic Name: | vorinostat |
| Code Name: | MK0683 |
| Company: | Merck Pharmaceuticals |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Zolinza (news articles), which is an approved drug for cutaneous T-cell lymphoma, is also being studied in combination with Velcade (bortezomib) for treatment of …
Read the full story »
| Brand Name: | |
| Generic Name: | perifosine |
| Code Name: | KRX-0401 |
| Company: | Keryx Biopharmaceuticals / Aeterna Zentaris |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Perifosine (news articles) is a novel anti-cancer agent that is being studied for its ability to inhibit Akt, a key signal transduction pathway. Akt is particularly important in the development of cancers, impacting programmed cell death, cell growth, cell …
Read the full story »
